JW Therapeutics (2126 HK)

JW Therapeutics is a clinical-stage cell therapy company focused on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product is Carteyva (relmacabtagene autoleucel), an autologous anti-CD19 CAR-T therapy. The company is headquartered in Shanghai, China, and was founded in 2016.